Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58


Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.

Jian Y, Chen X, Zhou H, Zhu W, Liu N, Geng C, Chen W.

Medicine (Baltimore). 2016 May;95(19):e3521. doi: 10.1097/MD.0000000000003521.


Genetic aberrations in multiple myeloma characterized by cIg-FISH: a Brazilian context.

Segges P, Braggio E, Minnicelli C, Hassan R, Zalcberg IR, Maiolino A.

Braz J Med Biol Res. 2016;49(5):e5034. doi: 10.1590/1414-431X20155034. Epub 2016 Apr 8.


Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Bladé J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R.

Blood. 2016 Jun 16;127(24):2955-62. doi: 10.1182/blood-2016-01-631200. Epub 2016 Mar 21.


Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.


Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.

Wang L, Wang H, Chen H, Wang WD, Chen XQ, Geng QR, Xia ZJ, Lu Y.

Oncotarget. 2015 Dec 1;6(38):41228-36. doi: 10.18632/oncotarget.5682.


Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.

Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):687-93. doi: 10.1016/j.clml.2015.07.641. Epub 2015 Aug 5.


Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF.

Haematologica. 2015 Oct;100(10):1327-33. doi: 10.3324/haematol.2014.117077. Epub 2015 Aug 6.


Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma.

Nishida Y, Matsue Y, Suehara Y, Fukumoto K, Fujisawa M, Takeuchi M, Ouchi E, Matsue K.

Blood Cancer J. 2015 Jul 31;5:e329. doi: 10.1038/bcj.2015.57.


MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

Lazareth A, Song XY, Coquin A, Harel S, Karlin L, Belhadj K, Roos-Weil D, Frenzel L, Tamburini J, Macro M, Chevret S, Loiseau HA, Minvielle S, Fermand JP, Soulier J, Bories JC, Arnulf B.

Haematologica. 2015 Nov;100(11):e471-4. doi: 10.3324/haematol.2015.127001. Epub 2015 Jul 23. No abstract available.


Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.

Gimsing P, Hjertner Ø, Abildgaard N, Andersen NF, Dahl TG, Gregersen H, Klausen TW, Mellqvist UH, Linder O, Lindås R, Tøffner Clausen N, Lenhoff S.

Bone Marrow Transplant. 2015 Oct;50(10):1306-11. doi: 10.1038/bmt.2015.125. Epub 2015 Jun 29.


Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials.

Liu X, He CK, Meng X, He L, Li K, Liang Q, Shao L, Liu S.

Onco Targets Ther. 2015 Jun 15;8:1459-69. doi: 10.2147/OTT.S84828. eCollection 2015.


Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance.

Qu X, Chen L, Qiu H, Lu H, Wu H, Qiu H, Liu P, Guo R, Li J.

Biomed Res Int. 2015;2015:787809. doi: 10.1155/2015/787809. Epub 2015 Apr 23.


The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.

Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B.

Leukemia. 2015 Aug;29(8):1713-20. doi: 10.1038/leu.2015.65. Epub 2015 Mar 10.


t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs.

Narita T, Inagaki A, Kobayashi T, Kuroda Y, Fukushima T, Nezu M, Fuchida S, Sakai H, Sekiguchi N, Sugiura I, Maeda Y, Takamatsu H, Tsukamoto N, Maruyama D, Kubota Y, Kojima M, Sunami K, Ono T, Ri M, Tobinai K, Iida S.

Blood Cancer J. 2015 Feb 27;5:e285. doi: 10.1038/bcj.2015.6. No abstract available.


Targeted treatments for multiple myeloma: specific role of carfilzomib.

Sugumar D, Keller J, Vij R.

Pharmgenomics Pers Med. 2015 Jan 20;8:23-33. doi: 10.2147/PGPM.S39085. eCollection 2015. Review.


Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.

Liu N, Zhou H, Yang G, Geng C, Jian Y, Guo H, Chen W.

Oncol Lett. 2015 Feb;9(2):930-936. Epub 2014 Dec 1.


An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.

Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M.

Eur J Haematol. 2015 Nov;95(5):426-35. doi: 10.1111/ejh.12509. Epub 2015 Mar 12.


The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma.

Prideaux SM, Conway O'Brien E, Chevassut TJ.

Bone Marrow Res. 2014;2014:526568. doi: 10.1155/2014/526568. Epub 2014 Sep 11.


RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.

Surget S, Descamps G, Brosseau C, Normant V, Maïga S, Gomez-Bougie P, Gouy-Colin N, Godon C, Béné MC, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.

BMC Cancer. 2014 Jun 14;14:437. doi: 10.1186/1471-2407-14-437.

Items per page

Supplemental Content

Write to the Help Desk